Altogether these results add mechanistic insight to the observation reported by Bosnakovski, D. et al. concerning the reduction in CDS tumor growth following p300 inhibition [20], and provide a new tangible therapeutic option that consists of a selective and potent p300 degrader [25]. Here, EP300 is linked to neoplasm.